Akasaka T, Onodera Y, Tanaka M, Sato K
New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Antimicrob Agents Chemother. 1999 Mar;43(3):530-6. doi: 10.1128/AAC.43.3.530.
The topoisomerase IV subunit A gene, parC homolog, has been cloned and sequenced from Pseudomonas aeruginosa PAO1, with cDNA encoding the N-terminal region of Escherichia coli parC used as a probe. The homolog and its upstream gene were presumed to be parC and parE through sequence homology with the parC and parE genes of other organisms. The deduced amino acid sequence of ParC and ParE showed 33 and 32% identity with that of the P. aeruginosa DNA gyrase subunits, GyrA and GyrB, respectively, and 69 and 75% identity with that of E. coli ParC and ParE, respectively. The putative ParC and ParE proteins were overexpressed and separately purified by use of a fusion system with a maltose-binding protein, and their enzymatic properties were examined. The reconstituted enzyme had ATP-dependent decatenation activity, which is the main catalytic activity of bacterial topoisomerase IV, and relaxing activities but had no supercoiling activity. So, the cloned genes were identified as P. aeruginosa topoisomerase IV genes. The inhibitory effects of quinolones on the activities of topoisomerase IV and DNA gyrase were compared. The 50% inhibitory concentrations of quinolones for the decatenation activity of topoisomerase IV were from five to eight times higher than those for the supercoiling activities of P. aeruginosa DNA gyrase. These results confirmed that topoisomerase IV is less sensitive to fluoroquinolones than is DNA gyrase and may be a secondary target of new quinolones in wild-type P. aeruginosa.
从铜绿假单胞菌PAO1中克隆并测序了拓扑异构酶IV亚基A基因(parC同源物),以编码大肠杆菌parC N端区域的cDNA作为探针。通过与其他生物的parC和parE基因的序列同源性,推测该同源物及其上游基因分别为parC和parE。推导的ParC和ParE氨基酸序列与铜绿假单胞菌DNA促旋酶亚基GyrA和GyrB的氨基酸序列分别具有33%和32%的同一性,与大肠杆菌ParC和ParE的氨基酸序列分别具有69%和75%的同一性。使用与麦芽糖结合蛋白的融合系统对推定的ParC和ParE蛋白进行了过表达和单独纯化,并检测了它们的酶学性质。重组酶具有ATP依赖性解连环活性,这是细菌拓扑异构酶IV的主要催化活性,还具有松弛活性,但没有超螺旋活性。因此,克隆的基因被鉴定为铜绿假单胞菌拓扑异构酶IV基因。比较了喹诺酮类药物对拓扑异构酶IV和DNA促旋酶活性的抑制作用。喹诺酮类药物对拓扑异构酶IV解连环活性的50%抑制浓度比对铜绿假单胞菌DNA促旋酶超螺旋活性的抑制浓度高五至八倍。这些结果证实,拓扑异构酶IV对氟喹诺酮类药物的敏感性低于DNA促旋酶,并且可能是野生型铜绿假单胞菌中新喹诺酮类药物的次要靶点。